SONN · Sonnet BioTherapeutics Holdings, Inc.

Sonnet Biotherapeutics Holdings, Inc., A Biotechnology Company Based In Princeton, New Jersey, Operates In The Clinical Stage With A Primary Focus On Oncology. The Firm Is Dedicated To Developing Novel Platforms For Creating Biologic Medicines That Can Exhibit Either Singular Or Dual Therapeutic Mechanisms. Central To Their Strategy Is A Proprietary Fully Human Albumin Binding Technology. This Innovative System Employs Human Single-Chain Antibody Fragments Specifically Engineered To Bind To Human Serum Albumin, Leveraging It For Enhanced Delivery And Transport To Target Tissues. Their Leading Therapeutic Candidate, Son-1010, Is A Fully Human Variant Of Interleukin 12, Currently Being Advanced For The Treatment Of Non-Small Cell Lung Cancer And Cancers Affecting The Head And Neck. Additionally, Sonnet Is Progressing Son-080, Another Fully Human Interleukin 6 Formulation, Intended To Address Both Chemotherapy-Induced And Diabetic Peripheral Neuropathy. The Company Also Maintains A Licensing Agreement With New Life Therapeutics Pte, Ltd., For The Development And Commercialization Of Pharmaceutical Preparations Containing A Specific Recombinant Human Interleukin 6.